Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial

2021 ◽  
Author(s):  
Ellen Boswijk ◽  
Marlies de Ligt ◽  
Marie-Fleur J Habets ◽  
Alma M.A. Mingels ◽  
Wouter D. van Marken Lichtenbelt ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Crossover Trial ◽  
Placebo Treatment ◽  
Fdg Uptake ◽  
Resveratrol Treatment ◽  
Randomized Crossover Trial ◽  
Arterial Inflammation ◽  
18F Fdg

Abstract Purpose Resveratrol has shown promising anti-inflammatory effects in in vitro and animal studies. We aimed to investigate this effect on arterial inflammation in vivo. Methods This was an additional analysis of a double-blind randomized crossover trial which included eight male subjects with decreased insulin sensitivity who underwent an 18F-fluoroxyglucose (18F-FDG) PET/CT after 34 days of placebo and resveratrol treatment (150 mg/day). 18F-FDG uptake was analyzed in the carotid arteries and the aorta, adipose tissue regions, spleen, and bone marrow as measures for arterial and systemic inflammation. Maximum target-to-background ratios (TBRmax) were compared between resveratrol and placebo treatment with the non-parametric Wilcoxon signed-rank test. Median values are shown with their interquartile range. Results Arterial 18F-FDG uptake was non-significantly higher after resveratrol treatment (TBRmax all vessels 1.7 (1.6–1.7)) in comparison to placebo treatment (1.5 (1.4–1.6); p=0.050). Only in visceral adipose tissue, the increase in 18F-FDG uptake after resveratrol reached statistical significance (p=0.024). Furthermore, CRP-levels were not significantly affected by resveratrol treatment (p=0.091). Conclusions Resveratrol failed to attenuate arterial or systemic inflammation as measured with 18F-FDG PET in subjects at risk of developing type 2 diabetes. However, validation of these findings in larger human studies is needed.

Time‐Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial

Obesity ◽  
2019 ◽  
Author(s):  
Amy T. Hutchison ◽  
Prashant Regmi ◽  
Emily N.C. Manoogian ◽  
Jason G. Fleischer ◽  
Gary A. Wittert ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
At Risk ◽  
Glucose Tolerance ◽  
Crossover Trial ◽  
Restricted Feeding ◽  
Randomized Crossover Trial

scholarly journals Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT

2022 ◽  
Vol 12 (1) ◽  
pp. 30
Author(s):  
José Raul Herance ◽  
Rafael Simó ◽  
Mayra Alejandra Velasquez ◽  
Bruno Paun ◽  
Daniel García-Leon ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Fdg Pet ◽  
Cardiovascular Events ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Myocardial Insulin Resistance

Background: Systemic insulin resistance is generally postulated as an independent risk factor of cardiovascular events in type 2 diabetes (T2D). However, the role of myocardial insulin resistance (mIR) remains to be clarified. Methods: Two 18F-FDG PET/CT scans were performed on forty-three T2D patients at baseline and after hyperinsulinemic–euglycemic clamp (HEC). Myocardial insulin sensitivity (mIS) was determined by measuring the increment in myocardial 18F-FDG uptake after HEC. Coronary artery calcium scoring (CACs) and myocardial radiodensity (mRD) were assessed by CT. Results: After HEC, seventeen patients exhibited a strikingly enhancement of myocardial 18F-FDG uptake and twenty-six a marginal increase, thus revealing mIS and mIR, respectively. Patients with mIR showed higher mRD (HU: 38.95 [33.81–44.06] vs. 30.82 [21.48–38.02]; p = 0.03) and CACs > 400 (AU: 52% vs. 29%; p = 0.002) than patients with mIS. In addition, HOMA-IR and mIS only showed a correlation in those patients with mIR. Conclusions: 18F-FDG PET combined with HEC is a reliable method for identifying patients with mIR. This subgroup of patients was found to be specifically at high risk of developing cardiovascular events and showed myocardial structural changes. Moreover, the gold-standard HOMA-IR index was only associated with mIR in this subgroup of patients. Our results open up a new avenue for stratifying patients with cardiovascular risk in T2D.

scholarly journals Pancreatic 18F-FDG uptake is increased in type 2 diabetes patients compared to non-diabetic controls

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0213202 ◽  
Author(s):  
Guido J. Bakker ◽  
Manon C. Vanbellinghen ◽  
Torsten P. Scheithauer ◽  
C. Bruce Verchere ◽  
Erik S. Stroes ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Fdg Uptake ◽  
18F Fdg ◽  
Diabetes Patients

Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial

2007 ◽  
Vol 9 (3) ◽  
pp. 394-407 ◽  
Author(s):  
S. S. Lund ◽  
L. Tarnow ◽  
C. D. A. Stehouwer ◽  
C. G. Schalkwijk ◽  
M. Frandsen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Crossover Trial ◽  
Obese Patients ◽  
Randomized Crossover Trial

Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial

2007 ◽  
Vol 154 (1) ◽  
pp. 78.e1-78.e7 ◽  
Author(s):  
Letícia Weiss Ribeiro ◽  
Jorge P. Ribeiro ◽  
Ricardo Stein ◽  
Cristiane Leitão ◽  
Carísi Anne Polanczyk
Keyword(s):  
Type 2 Diabetes ◽  
Crossover Trial ◽  
Randomized Crossover Trial

scholarly journals Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial

2021 ◽  
Author(s):  
Charlotte K. Boughton ◽  
Afroditi Tripyla ◽  
Sara Hartnell ◽  
Aideen Daly ◽  
David Herzig ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Primary Endpoint ◽  
Glucose Control ◽  
Closed Loop ◽  
Crossover Trial ◽  
Open Label ◽  
Randomized Crossover Trial ◽  
Target Glucose

AbstractWe evaluated the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis. In an open-label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68 ± 11 years (mean ± s.d.), diabetes duration of 20 ± 10 years) underwent two 20-day periods of unrestricted living, comparing the Cambridge fully closed-loop system using faster insulin aspart (‘closed-loop’) with standard insulin therapy and a masked continuous glucose monitor (‘control’) in random order. The primary endpoint was time in target glucose range (5.6–10.0 mmol l−1). Thirteen participants received closed-loop first and thirteen received control therapy first. The proportion of time in target glucose range (5.6–10.0 mmol l−1; primary endpoint) was 52.8 ± 12.5% with closed-loop versus 37.7 ± 20.5% with control; mean difference, 15.1 percentage points (95% CI 8.0–22.2; P < 0.001). Mean glucose was lower with closed-loop than control (10.1 ± 1.3 versus 11.6 ± 2.8 mmol l−1; P = 0.003). Time in hypoglycemia (<3.9 mmol l−1) was reduced with closed-loop versus control (median (IQR) 0.1 (0.0–0.4%) versus 0.2 (0.0–0.9%); P = 0.040). No severe hypoglycemia events occurred during the control period, whereas one severe hypoglycemic event occurred during the closed-loop period, but not during closed-loop operation. Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. The trial registration number is NCT04025775.

Sign in / Sign up

Export Citation Format

Share Document